Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.16 ▼ -0.03
(-2.52%)
MKT CAP: $207.4M • VOL: 3.09M
52W L $1 52W H $3
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
PALI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $250.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$18.1M | -$14.9M | -$13.1M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$16.8M | -$14.4M | -$12.3M |
| EBITDA (Normalized) | — | -$14.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.8M | -$12.2M | -$11.1M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$10.8M | -$12.2M | -$11.1M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $133.4M | $9.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $129.4M | $7.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PALI.